A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety,
efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid
tumors.